0000899243-19-004728.txt : 20190225
0000899243-19-004728.hdr.sgml : 20190225
20190225173846
ACCESSION NUMBER: 0000899243-19-004728
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190219
FILED AS OF DATE: 20190225
DATE AS OF CHANGE: 20190225
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: JOHNSON KENNETH ERLAND
CENTRAL INDEX KEY: 0001743774
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38536
FILM NUMBER: 19630764
MAIL ADDRESS:
STREET 1: C/O XERIS PHARMACEUTICALS, INC.
STREET 2: 180 N. LASALLE STREET, SUITE 1800
CITY: CHICAGO
STATE: IL
ZIP: 60601
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: XERIS PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001346302
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 203352427
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 180 NORTH LASALLE STREET
STREET 2: STE 1800
CITY: CHICAGO
STATE: IL
ZIP: 60601
BUSINESS PHONE: 512-498-2670
MAIL ADDRESS:
STREET 1: 180 NORTH LASALLE STREET
STREET 2: STE 1800
CITY: CHICAGO
STATE: IL
ZIP: 60601
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-02-19
0
0001346302
XERIS PHARMACEUTICALS INC
XERS
0001743774
JOHNSON KENNETH ERLAND
C/O XERIS PHARMACEUTICALS, INC.
180 N. LASALLE STREET, SUITE 1810
CHICAGO
IL
60601
0
1
0
0
See Remarks
Common Stock
2019-02-19
4
P
0
1000
10.00
A
3245
D
Mr. Johnson purchased shares of common stock from the underwriters in a public offering pursuant to the registrant's Registration Statement on Form S-1 (File No. 333-229665, completed on February 19, 2019). The shares of common stock were purchased at the public offering price.
Senior Vice President Clinical Development, Quality Assurance, and Medical Affairs
/s/ Beth Hecht
2019-02-25